{
    "nctId": "NCT02650635",
    "briefTitle": "TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",
    "officialTitle": "Phase IB Study Investigating the Tolerability, Immunomodulatory Impacts and, Therapeutic Correlates of the Novel Toll-like Receptor 8 Agonist Motolimod (MOTO) Plus Cyclophosphamide (CTX) Treatment of Advanced Solid Tumors",
    "overallStatus": "TERMINATED",
    "conditions": "Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Melanoma of the Skin, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 4,
    "primaryOutcomeMeasure": "Change in pharmacodynamics after TLR8 agonist VTX-2337 alone vs TLR8 agonist VTX-2337+cyclophosphamide",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed metastatic solid tumor, including but not limited to pancreatic adenocarcinoma, breast cancer, melanoma, renal cell carcinoma (RCC), colorectal adenocarcinoma, non-small cell lung cancer, and others approved by the principal investigator\n* Persistent, recurrent or progressive disease following at least one prior line of systemic therapy and there is no available therapy likely to improve survival\n* Measurable disease with \\>= 1 target lesion\n* White blood cells (WBC) \\>= 4200/mm\\^3\n* Absolute neutrophil count (ANC) \\>= 1400/mm\\^3\n* Platelets (PLT) \\>= 100,000/mm\\^3\n* Lymphocytes \\>= 700/mm\\^3\n* Hemoglobin \\>= 10 g/dL\n* Total bilirubin =\\< 1.5 X upper limit of normal (ULN) unless history of Gilbert's syndrome documented prior to first-line treatment of cancer and other liver function tests are within normal limits\n* Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =\\< 1.2 x ULN unless on anticoagulation medication with stable dosing for at least one month; in addition, patient must be able to stop taking medication for up to a week in order to have percutaneous biopsies of tumor tissue performed\n* Aspartate transaminase (AST) and alanine aminotransferase (ALT) =\\< 1.5 x ULN (=\\< 5 x ULN for patients with liver involvement)\n* Creatinine =\\< ULN or a calculated creatinine clearance of \\>= 45 ml/min if creatinine is greater than the ULN\n* Alkaline phosphatase =\\< 3 x ULN (=\\< 5 x ULN if liver or bone involvement)\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1\n* Willing and able to provide informed written consent\n* Willing and able to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing and able to return to the consenting institution for follow-up\n* Estimated life expectancy \\>= 84 days (3 months)\n* Willing and able to provide samples for correlative research purposes\n* If female of child-bearing potential, have a negative pregnancy test =\\< 14 days prior to registration\n* If fertile male or female of child-bearing potential, agree to consistently use a highly effective method of birth control (including birth control pills, barrier device, or intrauterine device) from the time of consent through 4 months following the last dose of study drug\n\nExclusion Criteria:\n\n* Is pregnant, breastfeeding, or planning a pregnancy\n* Known standard therapy for the patient's disease that is potentially curative\n* Treatment with any systemic anticancer treatment or an investigational agent within 4 weeks and any radiation within 2 weeks of registration\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit subject safety or compliance with study requirements\n* Active autoimmune disease, defined as any autoimmune condition currently requiring therapy (e.g., systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis)\n* History of other invasive malignancy, with the exception of non-melanoma skin cancer and well-excised cervical carcinoma in situ, =\\< 3 years prior to enrollment unless assessed by the principal investigator as unlikely to compromise subject safety or to interfere with the study's objectives\n* Treatment with oral or parenteral corticosteroids dosed greater than 40 mg hydrocortisone daily or its equivalent (e.g., prednisone 10 mg, prednisolone 8 mg, or decadron 3 mg) =\\< 2 weeks of treatment initiation; or a clinical requirement for ongoing systemic immunosuppressive therapy\n* History of central nervous system (CNS) metastases unless previously treated and stable for \\> 8 weeks prior to study initiation\n* Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive\n* Hypersensitivity to pegfilgrastim or Escherichia (E.) coli derived proteins",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}